Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H10N2O2 |
Molecular Weight | 178.1879 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)NC(=O)CC1=CC=CC=C1
InChI
InChIKey=XPFRXWCVYUEORT-UHFFFAOYSA-N
InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)
Molecular Formula | C9H10N2O2 |
Molecular Weight | 178.1879 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22512548
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22512548
Phenacemide, also known as phenylacetylurea, is an anticonvulsant of the ureide (acetylurea) class. Phenacemide was introduced in 1949 for the treatment of epilepsy, but was eventually withdrawn from the market because of its severe side effects, which includes personality changes, blood, renal and skin disorders.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331043 Sources: https://www.drugbank.ca/drugs/DB01121 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PHENURONE Approved UsePhenacemide, also known as phenylacetylurea, is an anticonvulsant of the ureide (acetylurea) class. Launch Date-5.8423679E11 |
Doses
Dose | Population | Adverse events |
---|---|---|
1.5 g 1 times / day steady, oral Dose: 1.5 g, 1 times / day Route: oral Route: steady Dose: 1.5 g, 1 times / day Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: psychomotor retardation Age Group: 16 years Sex: M Population Size: 1 Sources: |
Other AEs: Creatinine serum increased... |
2 g 1 times / day steady, oral Dose: 2 g, 1 times / day Route: oral Route: steady Dose: 2 g, 1 times / day Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: uncontrollable psychomotor epilepsy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Other AEs: Creatinine increased... |
3.5 g 1 times / day steady, oral Dose: 3.5 g, 1 times / day Route: oral Route: steady Dose: 3.5 g, 1 times / day Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: uncontrollable psychomotor epilepsy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Other AEs: Creatinine increased... |
2 g 1 times / day steady, oral Dose: 2 g, 1 times / day Route: oral Route: steady Dose: 2 g, 1 times / day Sources: |
unhealthy, 18 years n = 1 Health Status: unhealthy Condition: psychomotor retardation Age Group: 18 years Sex: M Population Size: 1 Sources: |
Other AEs: Creatinine serum increased... |
2.5 g 1 times / day steady, oral Dose: 2.5 g, 1 times / day Route: oral Route: steady Dose: 2.5 g, 1 times / day Sources: |
unhealthy, 18 years n = 1 Health Status: unhealthy Condition: psychomotor seizures Age Group: 18 years Sex: F Population Size: 1 Sources: |
Other AEs: Creatinine serum increased... |
4 g 1 times / day steady, oral Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: uncontrollable psychomotor epilepsy Age Group: 23 years Sex: M Population Size: 1 Sources: |
Other AEs: Creatinine increased... |
52 ug/mL steady, oral Dose: 52 ug/mL Route: oral Route: steady Dose: 52 ug/mL Sources: |
unhealthy, children n = 13 Health Status: unhealthy Condition: complex partial seizures Age Group: children Sex: unknown Population Size: 13 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Creatinine serum increased | 1 patient | 1.5 g 1 times / day steady, oral Dose: 1.5 g, 1 times / day Route: oral Route: steady Dose: 1.5 g, 1 times / day Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: psychomotor retardation Age Group: 16 years Sex: M Population Size: 1 Sources: |
Creatinine increased | 1 patient | 2 g 1 times / day steady, oral Dose: 2 g, 1 times / day Route: oral Route: steady Dose: 2 g, 1 times / day Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: uncontrollable psychomotor epilepsy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Creatinine increased | 1 patient | 3.5 g 1 times / day steady, oral Dose: 3.5 g, 1 times / day Route: oral Route: steady Dose: 3.5 g, 1 times / day Sources: |
unhealthy, 16 years n = 1 Health Status: unhealthy Condition: uncontrollable psychomotor epilepsy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Creatinine serum increased | 1 patient | 2 g 1 times / day steady, oral Dose: 2 g, 1 times / day Route: oral Route: steady Dose: 2 g, 1 times / day Sources: |
unhealthy, 18 years n = 1 Health Status: unhealthy Condition: psychomotor retardation Age Group: 18 years Sex: M Population Size: 1 Sources: |
Creatinine serum increased | 1 patient | 2.5 g 1 times / day steady, oral Dose: 2.5 g, 1 times / day Route: oral Route: steady Dose: 2.5 g, 1 times / day Sources: |
unhealthy, 18 years n = 1 Health Status: unhealthy Condition: psychomotor seizures Age Group: 18 years Sex: F Population Size: 1 Sources: |
Creatinine increased | 1 patient | 4 g 1 times / day steady, oral Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: |
unhealthy, 23 years n = 1 Health Status: unhealthy Condition: uncontrollable psychomotor epilepsy Age Group: 23 years Sex: M Population Size: 1 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13451900
Phenacemide was administered orally at 500-5000 mg daily dose
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:27:31 UTC 2023
by
admin
on
Fri Dec 15 16:27:31 UTC 2023
|
Record UNII |
PAI7J52V09
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
||
|
WHO-VATC |
QN03AX07
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
||
|
WHO-ATC |
N03AX07
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3380
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
DB01121
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
4753
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
7265
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
100000082226
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
SUB09744MIG
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
92
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
m8588
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | Merck Index | ||
|
200-570-2
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
39458
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
C66363
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
C005396
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
PAI7J52V09
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
63-98-9
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
2114
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
PHENACEMIDE
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
DTXSID6023442
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | |||
|
33253
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL918
Created by
admin on Fri Dec 15 16:27:31 UTC 2023 , Edited by admin on Fri Dec 15 16:27:31 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |